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in all 60 institutions enrolled. Patients with polytrauma were not
included into the study. The effects of prognostic factors were
analysed by uni- and multivariate logistic regression (p″T0.05)
in three groups: 1) all fracture-related treatments; 2) non-
prosthetic; and 3) prosthetic treatments. RESULTS: Out of 413
patients, 17.92% required further fracture-related treatment. In
7.75% non-prosthetic, and in 10.17% prosthetic treatment was
performed. We demonstrated the odds ratios by multivariate
regression analysis according to risk factors [95% conﬁdence
interval, CI] are also given. Fracture displacement ORf2.243,
CI:[1.036–4.858] weekend surgery ORf2.347, CI:[1.049–5.248],
infections ORf3.681, CI:[1.172–11.55], central nervous system-
related co-morbidities ORf3.639, CI:[1.421–9.318] and the
county hospital level of management ORf2.356, CI:[0.997–
5.568] were associated with signiﬁcantly increased risk for
further surgery. CONCLUSION: To reduce the inﬂuence of risk
factors, standardization of the substantive traumatologic and
orthopedic professional guidelines, as well as the introduction
of common orthopedic-trauma patient care (British model) are
suggested. To achieve high-quality standardized patient manage-
ment, personal and material conditions are required to be acces-
sible every day of the week. In the presence of co-morbidities,
reduction of their harmful effects should be a major consider-
ation by focusing on the patient both in the peri- and postopera-
tive periods.
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OBJECTIVES: The aim of the present study was to investigate
the relationship between the delay of deﬁnitive surgical treat-
ment and mortality rates occurring within 30 days post-injury
in patients aged 60 or older with femoral neck fracture.
METHODS: Data were obtained from the database of the
National Health Insurance Fund and from the questionnaire
survey carried out by the institutions providing the treatment.
Logistic regression analysis was performed to analyse the cor-
relation between mortality risks within 30 days and delayed
surgery in patients operated at 12–24 h, 24–48 h or after 48 h
post-injury in comparison with mortality risks associated with
early (within 12 h) treatment. RESULTS: The number of
patients meeting the case deﬁnition criteria was 3777 with the
average age of 77.97 years. Mortality rates in four groups were
7.7%, 10.5%, 10.5% and 9.4%, respectively. According to
multiple regression analysis, all three groups (12–24 h, 24–48 h
and the over 48 h) showed a trend to increased mortality risks
but this was not statistically signiﬁcant (OR12–24 h = 1.301
CI12–24 h: 0.945–1.791, p = 0.106; OR24–48 h = 1.384 CI24–
48 h: 0.932–2.056, p = 0.108; OR48 h <= .246 CI48 h <:
0.950–1.635, p = 0.113). Sex, age and accompanying diseases
signiﬁcantly inﬂuenced early mortality, while early post-
operative complications did not have a signiﬁcant impact on the
mortality risks. CONCLUSION: The results of the present
study indicate the importance of early surgery in the treatment
of femoral neck fractures in order to decrease early mortality
associated with the disease in the elderly populations. Our
results highlight the importance of further evaluating the
reasons behind the delay in the surgical treatment (problems
during treatment, difﬁculties in surgical access, co-morbidity
etc.), especially in cases when surgery is performed with a 24 h
or longer post-injury delay in order to determine factors that
inﬂuence the prognostic signiﬁcance of surgical delay in the case
of different patient groups.
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OBJECTIVES: With at least 150,000 osteoporotic fractures in
France, annual cost for osteoporosis consequences was estimated
to about €600 millions. Poor diagnosis rate led French authori-
ties to decide reimbursement of bone mineral densitometry
(BMD) for osteoporosis high risk population in July 2006 (i.e.
postmenopausal women with at least one risk factor as deﬁned
by the National Union of the Health Insurance Services). Our
study was aimed to estimate the prevalence of osteoporosis risk
factors so as to assess the economic impact of this case-ﬁnding
strategy. METHODS: This cross-sectional epidemiological
survey was carried out within a representative population of
women aged 45 years and over constituted using a stratiﬁed
random sampling method (age, sex, socio-professional group,
and employment status). Face-to-face home interviews deter-
mined eligibility of women for BMD-screening and whether they
had underwent a BMD and received a diagnosis of osteoporosis.
Direct costs were assessed from the perspective of the health care
providers (i.e. BMD and physician consultation: 39.96€ and
18.60€ respectively). RESULTS: In our sample, 79.6% (2081) of
women were menopaused. 51.8% of them were eligible for
BMD-screening and 11.6%were already diagnosed by BMD with
osteoporosis. Among the diagnosed women, a third (31.0%)
didn’t have any risk factors and would not be eligible for the
screening. Based on these results, number of French eligible
women for BMD-screening would be about 5.8 millions associ-
ated with a total cost of €342 millions. Women diagnosed by
BMD were 1.3 million and could also achieve 2.3 millions rep-
resenting a cost per patient screened of 165€. CONCLUSION:
According to this study, the French case-ﬁnding strategy for
postmenopausal osteoporosis would cost €342 millions and
would lead to treat an additional one million patients.
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OBJECTIVES: Medication compliance is a signiﬁcant factor con-
tributing to the clinical- and cost-effectiveness of therapy. This
study aimed to investigate the evidence on the overall cost of
non-compliance with medication, taking osteoporosis therapy as
an example. METHODS: The speciﬁc question addressed was
“What are the direct medical health care costs of non-compliance
and non-persistence in osteoporosis”. A Literature review was
conducted to search for publications presenting work under the
broad terms “costs”, “compliance/persistence” and “osteoporo-
sis”. The databases searched were Medline, EMBASE, and the
Cochrane Library. The listings were then appraised to identify
those papers relevant to the study question and for inclusion in
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